Montemagno, Christopher
Jacquel, Arnaud
Pandiani, Charlotte
Rastoin, Olivia
Dawaliby, Rosie
Schmitt, Thomas
Bourgoin, Maxence
Palenzuela, Héliciane
Rossi, Anne-Laure
Ambrosetti, Damien
Durivault, Jerome
Luciano, Frederic
Borchiellini, Delphine
Le Du, Julie
Gonçalves, Leticia Christina Pires
Auberger, Patrick
Benhida, Rachid
Kinget, Lisa
Beuselinck, Benoit
Ronco, Cyril
Pagès, Gilles
Dufies, Maeva http://orcid.org/0000-0003-1732-0388
Funding for this research was provided by:
A.R.Tu.R foundation (2019)
Agence Nationale de la Recherche (AAPG 2023)
Prince Albert II of Monaco Foundation (Government of the Principality of Monaco)
Fondation François-Xavier Mora (Fondation François-Xavier Mora)
Fondation de France (Fondation de France)
Article History
Received: 13 November 2023
Accepted: 14 February 2024
First Online: 19 March 2024
Declarations
:
: In vivo study approved by the Veterinary Service and the Direction of Sanitary and Social Action of Monaco.The study exclusively involved adult patients, aligning with ethical considerations. Patients and healthy donors signed informed consent, following the ethical principles of the Declaration of Helsinki and in accordance with recommendations set by an independent scientific review board. The research protocols underwent ethical approval from the ethics committee at each participating center and were conducted in accordance with the guidelines of the International Conference on Harmonization for Good Clinical Practice.
: All authors consent to publication.
: We disclose that RB, CR, GP, MD are the co-founders of the start-up Roca Therapeutics who develops RCT001.